Malignant melanoma is on the rise. There have been recent advances in targeted agents
and immunotherapies that have improved the management and treatment of patients with …

Immunostimulatory agents, including adjuvants, cytokines, and monoclonal antibodies, hold
great potential for the treatment of cancer. However, their direct administration often results …

Purpose: Cancer vaccines aim to generate and maintain antitumor immune responses. We
designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA …

The past decade has seen tremendous advances in both our understanding of cancer
immunosuppressive microenvironments and colonic bacteria facilitated by immune …

Metastatic melanoma therapies have proliferated over the last ten years. Prior to this,
decades passed with only very few drugs available to offer our patients, and even then …

Background. Patients with metastatic melanoma typically have a poor outcome; however, a
small proportion of patients achieve long-term survival (LTS). It is unclear how often LTS is …

Interleukin 21 (IL21) is a T-cell–derived 4-helix–bundle cytokine that has sequence
homology to the IL2 family. Recombinant human interleukin 2 (rIL2) is approved for the …

Patients with metastatic melanoma have a poor prognosis; the results of chemotherapy
remain unsatisfactory. Ipilimumab, an anticytotoxic T lymphocyte-associated antigen-4 …

Contrary to the impression that non-melanoma skin cancer is a banal and relatively trivial
malignancy it causes about 1% of all cancer deaths. Cutaneous Squamous Cell carcinoma …

Background Consensus statements and clinical practice guidelines are widely available for
enhancing the care of cancer patients. Despite subtle differences in their definition and …